Work

Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia

Year: 2025

Type: article

Source: Blood Advances

DOI: 10.1182/bloodadvances.2024015527

Authors: Olayinka Okeleji, David McCall, Amber Gibson, Miriam B. Garcia, Cesar Nunez, Michael Roth, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Branko Cuglievan, Irtiza N. Sheikh

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

OpenAlex ID: W4407897358

FWCI: 3.973

Cites: 23

Cited by: 6

Related to: 10